D.E. Shaw & Co
AKRO

D.E. Shaw & Co’s Akero Therapeutics AKRO Stock Holding History

D.E. Shaw & Co’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-20,000
Closed -$934K – 4227
2023
Q2 		$934K Buy
+20,000
New +$917K ﹤0.01% 3134

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

D.E. Shaw & Co's AKRO Position: Q4 2025 in Review

D.E. Shaw & Co sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 17,572 shares — an estimated $834K sold.

D.E. Shaw & Co first reported a position in AKRO in Q2 2022 and held it in 14 quarters. The position peaked at $19.2M in Q2 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • D.E. Shaw & Co reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 17,572 Akero Therapeutics shares in Q4 2025, an estimated $834K.
  • D.E. Shaw & Co first reported a position in Akero Therapeutics in Q2 2022 and held it in 14 quarters.
  • D.E. Shaw & Co's Akero Therapeutics position peaked at $19.2M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on D.E. Shaw & Co's 13F filing for Q4 2025, filed 17 Feb 2026.